1Ferlay J, Shin HR, Bray F, et al. Parkin DM. Estimates of world wide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer,2010,127(12) :2893-917.
2Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin,2007,57 ( 1 ) : 43-66.
3Wang F,Wang S,Wang Z,et al. Phosphorylated EGFR expression may predicts outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR[J]. J Exp Clin Cancer Res, 2012,31 ( 1 ) : 65.
4Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations (NEJ 003 study) [J]. J Thorac Oncol, 2012,7 (9):1417-22.
5Oizumi S,Kobayashi K,Inoue A,et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of north east Japan study group 002 trial[J]. Oncologist, 2012,17 (6) : 863-70.
6Kim ES, Hirsh V, Mok T, et al. Gefitinib versus doeetaxel in previously treated non-smalbeell lung cancer(INTEREST): arandomised phase Ⅲ trial [J]. Lancet, 2008, 372 (9652): 1809-18.
7Fukuoka M,Wu YL,Thongprasert S,et al. Biomarker analyses and final overall survival results from a phase Ⅲ,randomized, open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients'with advanced non-small- cell lung cancer in Asia (IPASS) [ J ]. J Clin Oncol, 2011,29 (21): 2866-74.
8Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patient with non small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010,11 (2) : 121-8.
9Tony SK,Manolo D, Raffaele C. Clinical outcomes with Erlo tinib in patients with epidermal growth factor receptor mutation(NEJGSG002) [J]. Drugs,2012(72) :3-10.
10Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer(INFORM: C-TONG 0804) : a multicentre,double blind randomised phase 3 trial[J]. Lancet Oncol,13(5) :466-75.
5Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevaxizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355(24): 2542-2550.
6Laurie SA, Arnold A, Shepherd FA, et al. National Cancer Institute of Canada clinical trials group study BR.24, a randomized placebo controlled phase Ⅱ trial ofcediranib (CED) plus carboplatin+paclitaxel (C+P) in advanced nonsmall cell lung cancer of any histology: Further analyses. J Thorac Oncol, 2008, 3 (suppl): S304.
7Kim ES, Kies MS, Fosssella FV, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/ resistant non small cell luang carcinoma. Cancer, 2005, 104(3): 561-569.
8Reck M, von Pawel J, Zatloukal P, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol, 2009, 27(8): 1227-1234.
9Herbst RS, Blumenschein Jr GR, Kim ES, et al. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. Proc ASCO, 2010, 28: 15s (suppl; abstr 7609).
10Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib (SU) in combination with Erlotinib (E) for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): a phase III study. Ann Oncol, 2010, 21(S8): viiil-viiil2 (Abstract LBA6).
